ASH 2018 | Updates from MURANO for CLL: time-limited VenR & impact of MRD
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
John Seymour, MBBS, FRACP, PhD, of the Peter MacCallum Cancer Centre, East Melbourne, Australia, gives us the key updates from the MURANO study (NCT02005471) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. This included establishing a time-limited venetoclax-rituximab regimen for relapsed/refractory chronic lymphocytic leukemia (CLL), and the first prospective data on the impact of MRD on long-term outcomes after this therapy.
Get great new content delivered to your inboxSign up